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To identify new potential substrates for the MAP kinase sig-
nal-integrating kinases (Mnks), we employed a proteomic
approach. TheMnks are targeted to the translationalmachinery
through their interaction with the cap-binding initiation factor
complex.We testedwhether proteins retained on cap resinwere
substrates for theMnks in vitro, and identified one such protein
as PSF (the PTB (polypyrimidine tract-binding protein)-associ-
ated splicing factor). Mnks phosphorylate PSF at two sites in
vitro, andour data show that PSF is anMnk substrate in vivo.We
also demonstrate that PSF, together with its partner, p54nrb,
binds RNAs that contain AU-rich elements (AREs), such as
those for proinflammatory cytokines (e.g. tumor necrosis factor
 (TNF)). Indeed, PSF associates specifically with the TNF
mRNA in living cells. PSF is phosphorylated at two sites by the
Mnks. Our data show that Mnk-mediated phosphorylation
increases the binding of PSF to the TNFmRNA in living cells.
These findings identify a novelMnk substrate. They also suggest
that the Mnk-catalyzed phosphorylation of PSF may regulate
the fate of specific mRNAs by modulating their binding to
PSFp54nrb.
Polypyrimidine tract-binding protein (PTB)3-associated
splicing factor (PSF) and p54nrb are highly homologous DNA/
RNA-binding proteins that form a multifunctional het-
erodimer implicated in nuclear processes such as transcription,
nuclear RNA processing, nuclear retention of edited RNA,
DNA relaxation, and tumorigenesis (reviewed in Ref. 1). These
proteins also cooperate in the inhibition of human immunode-
ficiency virus type 1 mRNA expression (2). Moreover, PSF is
also been reported to repress gene expression through its asso-
ciation with nuclear hormone receptors (3) or through binding
to insulin-like growth factor-1 response elements (4). PSF and
p54nrb are both phosphoproteins. Phosphorylation may be
involved in the relocalization of PSF during apoptosis (5) and in
regulating the binding properties of p54nrb during mitosis (6).
All eukaryotic cytoplasmic mRNAs have a 5-terminal cap
structure that contains 7-methyl-GTP (m7GTP) and promotes
their efficient translation (7, 8). The cap is bound by eukary-
otic translation initiation factor eIF4E, which also binds to
the scaffold eIF4G and through this with other translational
factors to recruit the 40 S ribosomal subunit to the mRNA.
eIF4G also binds the poly(A)-binding protein (PABP), which
interacts with the 3-end of the mRNA, thus circularizing it
(reviewed in Ref. 9).
eIF4E is phosphorylated in vitro and in vivo by the MAP
kinase-signal integrating (or MAP kinase-interacting) kinases
(Mnks) (10–13). There are two Mnk genes in humans, each of
which generates two different polypeptides as a consequence of
alternative splicing (14, 15). The longer Mnk1 isoform, Mnk1a,
is switched on by signaling through the ERK and p38 MAP
kinase pathways, whereasMnk2a (the longerMnk2 isoform), in
contrast, shows high basal activity (11, 16, 17). We recently
showed that Mnks play an important role in the control of the
production of the proinflammatory cytokine tumor necrosis
factor  (TNF) in T-cells (18).
The 3-untranslated regions of the TNF mRNA and many
other cytokines contain regulatory AU-rich elements (AREs),
which regulate their stability and/or translation through their
interaction with ARE-binding proteins (19). Specific stimuli
increase the stability and/or translation of such mRNAs, and
this is important in controlling the production of cytokines
such as TNF (reviewed Ref. 20), which is regulated through
signaling pathways that include ERK and p38 MAP kinase /
(21), i.e. the pathways that regulate Mnk1. Here, we show that
PSFp54nrb interacts with ARE-containing RNAs and that PSF
is phosphorylated and regulated by the Mnks.
MATERIALS ANDMETHODS
Chemicals—All chemicals and biochemicals were from
Sigma.
Antibodies—These were obtained as follows: anti-human
eIF4E was raised against a synthetic peptide corresponding to
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residues 5–23 of the protein, anti-PSF phospho-Ser8 was raised
against a synthetic peptide corresponding to residues 2–13 of
the protein (at Diagnostics Scotland), anti-eIF4G and anti-
PABPwere kindly provided byDr. SimonMorley (University of
Sussex). Anti-human CD3 was a kind gift from Dr. R. Vilella
(Hospital Clinic, Barcelona) and was used at 1:1000 dilution.
Anti-human CD28 was a kind gift from Dr. Pedro Romero
(Ludwig Institute for Cancer Research, Switzerland) and was
used as a hybridoma supernatant at 1:20 dilution. Other anti-
bodies used were anti-p54nrb (BD Transduction Lab), anti-PSF
(monoclonal antibody, clone B92, Sigma), anti-TIA-1 (C-20,
Santa Cruz Biotechnologies), anti-hemagglutinin (monoclonal
antibody, Roche Diagnostics), anti-myc and anti-FLAGmono-
clonal antibodies (Sigma), anti--tubulin and anti-lamin B
(Santa Cruz Biotechnology).
Affinity Resins—7-Methyl-GTP-Sepharose 4B was from
AmershamBiosciences, SepharoseCL-4B (control fornonspecific
binding to Sepharose beads) was from Sigma, nickel-nitrilotriace-
tic acid agarose was from Qiagen, and streptavidin-agarose from
Invitrogen.
Plasmids—pET15b-PSF was a kind gift from Dr. James Pat-
ton (Vanderbilt University), pET15b-p54nrb was obtained from
pEYFP-p54nrb kindly provided by Dr. Archa H. Fox (University
of Dundee), pRK7-4EHP was a kind gift from Dr. Andrew R.
Tee (now University of Cardiff), and pCDNA3-CBP20 was a
kind gift fromDr. Richard Cerione (Departments of Chemistry
and Chemical Biology and Molecular Medicine, Cornell Uni-
versity, Ithaca, New York).
Protein Expression and Purification—Recombinant eIF4E
was obtained as described previously (22). Recombinant PSF
and p54nrb were expressed as His-tagged proteins in Esche-
richia coli strainBL21. Briefly, after a 5-h inductionwith 0.5mM
isopropyl -D-thiogalactopyranoside at 30 °C, cells expressing
PSF or p54nrb were resuspended in buffer A (50 mM NaH2PO4,
0.3 M NaCl, 20 mM imidazole, pH 8). After one freeze-thaw
cycle, cells were incubated for 30 min on ice with 5 mg of
lysozyme per liter of bacteria culture. After sonication, 1% (v/v)
Triton X-100 and 5% (v/v) glycerol were added, and after a
15-min incubation on ice, cells were centrifuged for 30 min at
10,000  g. Proteins were pulled down from the supernatant
with 300 l of nickel (Ni)-agarose resin. After elution of the
proteins with 300 mM imidazole, they were dialyzed 3 times for
1 h and 30 min at 4 °C against buffer B (50 mM NaH2PO4, 150
mM NaCl, 5% glycerol, pH 7.7).
RNA Affinity Chromatography—RNA affinity chromatogra-
phy was performed as described (23) with biotinylated RNA
oligoribonucleotides encoding the AU-rich region of mouse
TNF (UUAUUAUUUAUUAUUUAUUUAUUAUUUAUU-
UAUUU), mouse granulocyte-macrophage colony stimulating
factor (UUUUUAAAUAUUUAUUUAUUUAUUUAUUUAA-
UUUU), human c-Fos (GUUUUUAAUUUAUUUAUUAAG-
AUGGAUUCU), mouse interferon  (AAACCUAUUUAUU-
AAUAUUUAAAACUAUUUAUAUG), human COX-2 (CUA-
AUGAUCAUAUUUAUUUAUUUAUAUGAACCAUG), or a
negative-control sequence (AAGCUUGGGCUGCAGGUCG-
ACUCUAGAGGA). The TNF and negative-control oligo
RNAs were purchased from Dharmacon, the rest were a kind
gift fromDr. SimonRousseau (University ofDundee, Scotland).
In Vitro Binding Assays—In vitro RNA-binding assays were
performed in lysis buffer containing 20mMHEPES (pH 7.4), 50
mM KCl, 50 mM -glycerophosphate, 0.2 mM EDTA, 1% Triton
X-100, 10% glycerol, 1 g/ml leupeptin, 1 g/ml pepstatin, 1
g/ml antipain, 1 mM benzamidine, and 1 mM dithiothreitol
supplemented with 5 g/l bovine serum albumin. The speci-
fied protein(s) (PSF, p54nrb, and/or eIF4E, 30 pmol) and, where
indicated, 175 pmol of biotinylated oligoribonucleotide con-
taining the TNF AREs, were incubated for 1 h at 4 °C prior to
the addition of the resin (m7GTP-Sepharose, Sepharose CL-4B,
nickel-agarose, or streptavidin-agarose beads, 15 l of packed
beads). Themixturewas then incubated for a further 1 h at 4 °C.
Then the beadswerewashed 3 timeswith lysis buffer and resus-
pended in SDS sample buffer to be analyzed by SDS-PAGE and
immunoblotting.
Resin Chromatography—After washing with PBS, 1 10-cm
plate of human embryonic kidney (HEK) 293 cells were lysed
with 400 l of 20 mM HEPES (pH 7.4), 50 mM KCl, 50 mM
-glycerophosphate, 0.2 mM EDTA, 1% Triton X-100, 10%
glycerol, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 g/ml anti-
pain, 1 mM benzamidine, and 1 mM dithiothreitol. The lysates
were centrifuged for 5 min at 10,000 g to remove cell debris.
The supernatant was incubated with 20 l of packed beads of
m7GTP-Sepharose or Sepharose CL-4B. After 2 h the beads
were washed 3 times with lysis buffer. Unless stated otherwise,
beads were resuspended in SDS sample buffer to be analyzed by
SDS-PAGE and immunoblotting. The material retained on
m7GTP-Sepharose was incubated with 0.1mg/ml RNase A and
160 units/ml RNase T1 at 16 °C for various times (see legends).
Immunoprecipitations—2 g of anti-myc, 6 g of anti-PSF,
or 15 g of anti-FLAG antibodies were added to 300 g of cell
extracts, and the mixture was incubated for 1 h at 4 °C. Subse-
quently, proteinG-Sepharose (20l of packed beads per immu-
noprecipitation) in wash buffer (lysis buffer without Triton
X-100) were added and allowed to bind the antibody for an
additional hour at 4 °C. The beads were then washed three
times with 500l of this wash buffer and finally resuspended in
SDS-PAGE loading buffer.
Ribonucleoprotein Immunoprecipitation Assay—Reversible
cross-linking combined with IP to study RNA-protein interac-
tions in vivo was performed as described previously (24).
Briefly, 30  106 Jurkat cells left untreated or activated with
anti-CD3/anti-CD28 for 1.5 h were incubated with phosphate-
buffered saline containing 1% formaldehyde. Sonicated lysates
were subjected to IP with 20 g of anti-PSF antibody. After
extensivewashing, the beadswere incubated at 70 °C for 45min
to reverse the cross-links, the RNA was purified using TRIzol
(according to the manufacturer’s instructions, Invitrogen), and
the immunoprecipitated RNAwas analyzed by RT-PCR or RT-
quantitative (Q)-PCR.
RT-PCR and RT-Q-PCRAmplification Analysis—Total RNA
extracted using the RNeasy kit (Qiagen) or RNA extracted from
the PSF immunoprecipitates (TRIzol method, Invitrogen) were
treated with 160 units/ml RNase-free DNase I and then sub-
jected to reverse transcription using SuperScript III (Invitro-
gen) and oligo(dT)15/Random primers (Invitrogen) following
the manufacturer’s instructions. Subsequently, PCR using the
Platinum Taq DNA Polymerase (Invitrogen) was performed
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using specific primers to amplify cDNAs for either glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) or TNF. The
primers used here are TCGGAGTCAACGGATTTGGTCG
and AGCAGGGATGATGTTCTGGAGAG for GAPDH, and
CAGAGGGAAGAGTTCCCCAG and CCTTGGTCTGG-
TAGGAGACG for TNF.
For RT-Q-PCR analysis, TaqMan Gene expression assays
(Applied Biosystems) were used. References are Hs00174128_m1
for human TNF, Hs99999901_s1 for the 18 S ribosomal RNA,
and Hs00174086_m1 for interleukin-10.
SDS-PAGE and Immunoblotting—Cell lysates were prepared
in Laemmli sample buffer and heated for 5 min at 95 °C. Poly-
acrylamide gels raging from 10 to 15% were used to analyze
protein content of the lysates. The proteins were either trans-
ferred onto polyvinylidene difluoride membranes and detected
byWestern blot analysis orwere transferred onto nitrocellulose
membranes and detected by a fluorescence-based detection
method (using the LiCOR OdysseyTM system).
Cell Culture and Transfection Experiments—Jurkat T-cells
were grown in a 5% CO2 incubator at 37 °C in Dulbecco’s mod-
ified Eagle’s medium containing 10% (v/v) heat-inactivated
serum, penicillin (100 units/ml), and streptomycin (100g/ml).
HEK293 cells were maintained in Dulbecco’s modified
Eagle’smedium supplementedwith 10% (v/v) serum, penicillin,
and streptomycin and cultured in 10-cm dishes in a 5% CO2
incubator at 37 °C. HEK293 cells were transfected using the
calcium phosphate method whereby a calcium/phosphate (125
mMCaCl2, 50mMBES, 280mMNaCl, 1.5mM sodium hydrogen
orthophosphate)/DNA co-precipitate is added to the cells.
HEK293 cells were split to a density of 2 106 cells per 10-cm
diameter dish and after 8 h at 37 °C in complete Dulbecco’s
modified Eagle’s medium, cells were transfected with 1 g/ml
DNA co-precipitated per dish. After transfection, cells were
placed in the incubator at 37 °C and 5% CO2. If cells were to be
stimulated, 24 h after transfection they were starved of serum
overnight and then stimulated. Otherwise they were lysed 36 h
after transfection.Where non-transfected cells were used, they
were starved of serum overnight prior to stimulation, and then
stimulated with 100 nM insulin, 1 M tetradecanoylphorbol
13-acetate (TPA), or 100 M arsenite for 30 min.
In Vitro Protein Kinase Assays and Peptide Mapping—Re-
combinantHis-taggedMnk1 or -2 (0.04g/l) was activated in
vitro with active SAPK2 (p38 MAPK, final concentration, 1
unit/ml; fromDSTT,University of Dundee) and 100MATP in
kinase buffer (100 mM HEPES-KOH, pH 7.4, 250 mM KCl, 50
mM MgCl2, 25% glycerol, 1 mM dithiothreitol, and 0.5 mM
Na3VO4). After 2 h at 30 °C, SB203580 at a final concentration
of 10 M was added. 5 l of active Mnk was used to phospho-
rylate proteins bound to 20 l of m7GTP-Sepharose in vitro in
the presence of 100MATP and [-32P]ATP. The reaction was
stopped by adding Laemmli buffer with 10 mM dithiothreitol
and heating for 5 min at 95 °C. Phosphorylated proteins were
separated in a 15% acrylamide/bisacrylamide gel. Labeled
bands detected by autoradiography were excised and subjected
to tryptic digestion (25). Phosphopeptides were detected by
precursor ion scanning in the negative ion mode as described
previously (26).
Active Mnk1 or -2 was also used to phosphorylate recombi-
nant PSF. The reaction was stopped by adding Laemmli dena-
turing buffer containing 10 mM dithiothreitol and heating for 5
min at 95 °C. Cysteines were alkylated with iodoacetamide for
45 min at 30 °C and proteins separated by SDS-PAGE. The
labeled protein was excised from the gel and digested overnight
with trypsin. Samples were acidified by adding 3 volumes of
0.1% trifluoroacetic acid in acetonitrile and peptides were sep-
arated by reverse-phase chromatography on a Vydac C18
(250  4.6 mm inner diameter) column equilibrated in 0.1%
trifluoroacetic acid and developed with a gradient of acetoni-
trile. Fractions containing radioactivity were collected and ana-
lyzed by mass spectrometry (MALDI-TOF) and solid-phase
sequencing. Two-dimensional mapping was described previ-
ously (27) using a second dimension buffer containing isobu-
tyric acid.
Cellular Fractionation—10 106 Jurkat cells were harvested
in 300 l of EZ lysis buffer (Sigma) with the addition of 1 mM
dithiothreitol, 0.5 mM sodium orthovanadate, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM benzamidine, 1 g/ml each of
leupeptin, antipain, and pepstatin. After centrifugation for 5
min at 1,000  g at 4 °C, the cytoplasmic fraction was trans-
FIGURE 1. Identification of PSF as a potential Mnk substrate in cap resin-
bound material. A, kinase assay using Mnk1 and proteins isolated in an
m7GTP-Sepharose pull-down from insulin-treated HEK293 cells. 20 l of
m7GTP-Sepharose beads were used to isolate proteins from one 10-cm plate
of HEK293 cells stimulated with 100 nM insulin for 30 min. This quantity of
material was used in each kinase assay. This figure is an autoradiograph. The
indicated radiolabeled proteins were identified by tryptic mass fingerprint.
Other bands were present either in the Mnk or samples-only lanes, and were
therefore not studied further. B, Western blots from m7GTP- and Sepharose
CL-4B pull-downs from growing HEK293 cells. Immunoblots were developed
with the indicated antibodies. As La was not detected in the pull-down, the
sample of cell lysate is shown as a “positive control.”
TABLE 1
Identification by mass fingerprinting of proteins retained onm7GTP-
Sepharose, phosphorylated by Mnk1 (Fig. 1A)
Name of
protein matched
Protein
accession No.
Mass of
protein
Species
matched to Score
a
kDa
eIF4G 3,941,724 172.2 Human 184
PSF 4,826,998 76.2 Human 92
Mnk 10,946,850 47.2 Human 95
a Score is 10  log(P), where P is the probability that the observed match is a
random event. Protein scores greater than 73 are significant (p 0.05).
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ferred to a new tube. The nuclear pellet was washed twice with
500 l of EZ Lysis buffer and then lysed by addition of SDS-
PAGE sample buffer.
RESULTS
Mnks Phosphorylate PSF in Vitro—Because theMnks bind to
the eIF4F cap-binding complex and phosphorylate at least two
of its components, eIF4E and eIF4G (10, 28), we reasoned that
additional proteins associated with this complex might be sub-
strates for the Mnks. We therefore performed affinity purifica-
tions from cytoplasmic lysates of HEK293 cells using m7GTP-
Sepharose beads and incubated the bound material with highly
active Mnk1 and [-32P]ATP (i.e. using a modified version of the
KESTREL procedure (29)). The reaction products were analyzed
by SDS-PAGE and autoradiography. Four major radiolabeled
FIGURE 2. PSFp54nrb do not bind directly to eIF4E, 4E-HP, or CBP20. A, 30
pmol of His-PSF, His-p54nrb, and/or untagged recombinant eIF4E (made in bac-
teria) were used in in vitro binding assays with nickel-agarose beads (SN, super-
natant). B, Western blots from anti-PSF or anti-myc immunoprecipitates (IP)
obtained from insulin-stimulated (100 nM, 30 min) HEK293 cells that had been
transfectedwithpCS3MT-eIF4E(myc-taggedeIF4E)orwithemptyvector(V).C,West-
ernblotsfromanti-PSForanti-FLAGimmunoprecipitatesobtainedfrominsulin-stim-
ulated (100nM,30min)HEK293cells transfectedwithpRK7–4EHP (FLAG-tagged)or
empty vector (V). D, as B but HEK293 cells were transfected with pcDNA3-CBP20
(hemagglutinin-tagged CBP20) or empty vector (Vector) and immunoprecipitates
prepared from lysates fromserum-fedcells, usinganti-hemagglutinin.
FIGURE 3. Characterization of the retention of PSFp54nrb on m7GTP-
Sepharose. A, 30 pmol of recombinant His-PSF or His-p54nrb made in E. coli
were assayed in vitro for binding to m7GTP-Sepharose or Sepharose CL-4B.
B, HEK293 cell extracts (300 g of protein) were supplemented with GTP or
m7GTP (at 0.5 or 1 mM) and then subjected to m7GTP-Sepharose pull-down.
The presence of PSFp54nrb and eIF4E on the resin was analyzed by Western
blotting. C, Western blots from RNase-treated (0.1 mg/ml RNase A and 160
units/ml RNase T1 at 16 °C for the times indicated) and control (mock)m7GTP-
Sepharose pull downs from insulin-stimulated HEK293 cells. The signal for
eIF4E (the component that binds directly to the resin) serves as the “loading
control” for interpreting the data for the other antibodies.
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bands were observed (Fig. 1A). The
lowest molecular weight band, as
judged from its electrophoretic mo-
bility corresponded to eIF4E. A
prominent band corresponded to the
added Mnk (see kinase-only (Mnk1)
lane in Fig. 1A), which undergoes
extensive autophosphorylation
(Mnk was also identified by mass
spectrometry, Table 1).
Two other major radiolabeled
bands were excised from the gel. The
proteins contained in these bands
were identifiedby trypticmass finger-
print analysis as eIF4G and PSF (Fig.
1A, Table 1). Although eIF4G and
eIF4E are known to be retained on
m7GTP-Sepharose and be substrates
for the Mnks, PSF has not previously
been reported to be retained on the
cap resin or to be an Mnk substrate.
The identification of PSF was con-
firmed by Western blot analysis (Fig.
1B). Also present among the proteins
that bound m7GTP-Sepharose was
p54nrb, which associates with PSF (1)
(Fig. 1B), as well as PABP, which
interacts with eIF4G (30). In contrast,
the RNA-binding protein La was not
retained on the m7GTP-Sepharose
resin (Fig. 1B).
PSFp54nrb Do Not Bind Directly
to eIF4E or to m7GTP—There were
several possible reasons why PSF
p54nrb might be found in material
isolated on m7GTP-Sepharose: (i) one or both proteins bind
directly to eIF4E (or another cap-binding protein such as, the
cap-binding complex component CBP20 (31) or the eIF4E-ho-
mologous protein, 4E-HP (32)); (ii) one or both proteins bind to
them7GTP-cap resin directly; or (iii) they are brought down on
the cap resin through their interactionwith RNA,which in turn
is bound by proteins such as eIF4A, eIF4B, and PABP, all of
which bind eIF4G, and thus are indirectly associated with
eIF4E. They can therefore be isolated on the cap resin (33).
Neither PSF nor p54nrb contains theYXXXXmotif (where
 represents a hydrophobic residue) found in bona fide eIF4E-
binding proteins (34), so it seemed unlikely that they bound to
eIF4E in the same way as, for example, eIF4G. However, it was
possible that one or both did so via a different type of interac-
tion with eIF4E. To test for a direct interaction between eIF4E
andPSFp54nrb, we studiedwhether recombinant hexahistidine
(His6)-tagged PSFp54nrb bound recombinant eIF4E. His6-PSF/
His6-p54nrb was, as expected, retained on nickel-agarose,
whereas eIF4E was not.When eIF4E wasmixed with His6-PSF/
His6-p54nrb prior to incubation with nickel-agarose, the
PSFp54nrb was again retained on the beads, but eIF4E was not
(Fig. 2A). In similar experiments, recombinant eIF4E did bind
to a known partner, eIF4E-binding protein 1, demonstrating
the utility of the approach (data not shown).
As a further test, eIF4E was expressed in HEK293 cells as a
myc-tagged fusion, and immunoprecipitatedwith anti-myc.No
PSF or p54nrb was recovered in the immunoprecipitate,
whereas eIF4G (a positive control that binds directly to eIF4E)
was recovered in this fraction (Fig. 2B). These findings again
indicate the absence of a direct interaction of PSFp54nrb with
eIF4E or, probably, with eIF4G.
To test for possible interactions with two other m7GTP-
binding proteins, 4E-HP and CBP20, these proteins were indi-
vidually expressed as FLAG- or hemagglutinin-tagged fusions
in HEK293 cells, and then immunoprecipitated from the
lysates. This did not result in the co-precipitation of PSF or
p54nrb, indicating that neither of these cap-binding proteins
interacts with PSFp54nrb either directly or indirectly (Fig. 2, C
and D).
To test whether PSF or p54nrb could bind directly tom7GTP,
purified recombinant PSF and p54nrb (made in bacteria, which
lacks cap-binding proteins) were mixed with m7GTP-Sepha-
rose or, as a negative control, CL-4B beads. Very little retention
of either protein on the beads was seen (Fig. 3A). Nevertheless,
it remained possible that PSFp54nrb did interact directly with
FIGURE 4. PSFp54nrb bind to ARE-containing RNAs. A, Western blot from pull-downs from Jurkat T-cells
using TNF-based or control oligoribonucleotide. B, Western blot from pull-downs with biotinylated oligori-
bonucleotides containing the AREs from the TNF, granulocyte-macrophage colony stimulating factor (GM-
CSF), c-Fos, interferon , and cyclooxygenase (COX) 2 mRNAs, or a negative control (Con). C, in vitro binding of
recombinant (Rec.) His6-PSF and/or His6-p54
nrb to streptavidin-agarose beads in the presence or absence of
biotinylated TNF oligoribonucleotide (TNF oligo). Western blots for PSF (left) and p54nrb (right) in the bound
material (StAg) or supernatants (SN) are shown. D, TNF and GAPDH mRNA levels in anti-PSF IPs or total cell
lysates from Jurkat cells, determined by RT-PCR. E, the amounts of GM-CSF mRNA co-immunoprecipitating
with PSF were assessed by quantitative PCR following reverse transcription of the RNA. The data are averaged
for duplicates performed, similar data being obtained in three independent experiments, and are shown
relative to the signal for the “no Ab” negative control.
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the m7GTP-Sepharose beads, al-
though because PSF and p54nrb are
both nucleotide (RNA)-binding
proteins, the interaction could be
nonspecific. We therefore studied
the specificity of the binding of
PSFp54nrb to this resin. To do this,
we assessed the ability of PSF
p54nrb, and as a control for a genu-
ine m7GTP-binding protein, eIF4E,
to bind m7GTP-Sepharose in the
presence of an excess of freem7GTP
or GTP nucleotides. As shown in
Fig. 3B, eIF4E was not retained on
the resin in the presence of m7GTP
(as expected), whereas PSFp54nrb
was excluded by either m7GTP or
GTP. These data suggest that PSF or
p54nrb (or other components of
nucleoprotein complexes in which
they are involved) can bind to nucle-
otide affinity resins.
To test whether PSFp54nrb asso-
ciated with the cap resin via binding
to RNAs that are pulled down with
this resin, we tested whether its
recovery on m7GTP-Sepharose was
affected by pretreatment of the
bound material with RNase. As
shown in Fig. 3C, treatment with
ribonucleases A plus T1, but not
“mock” incubation in the absence of
nuclease, greatly decreased the
amount of PSF and p54nrb that was
recovered in this way. Incubation
had a small effect on the binding of
eIF4G (whichwas the same for incu-
bation with or without RNase) but
essentially no effect on the amount
of eIF4E recovered except at the
final time point of the mock incuba-
tion where a modest decrease in all
proteins was observed. Thus, it appears that the appearance of
PSFp54nrb in the cap resin-boundmaterial is due to their asso-
ciation with RNAs that are present in this material. A key ques-
tion was therefore: do PSFp54nrb bind nonspecifically to
mRNAs or are they preferentially associated with specific
messages?
PSFp54nrb Bind ARE-containing RNAs—PSFwas found dur-
ing a study of proteins that bind to an oligoribonucleotide cor-
responding to the AU-rich element of the TNF mRNA.4 To
confirm this, we used a biotinylated oligoribonucleotide con-
taining the AREs of the TNFmRNA and, as negative control,
one lacking AREs. PSF and p54nrb were retained on the ARE-
containing oligoribonucleotide but not the negative control
(Fig. 4A). A negative control protein, eIF4G, was not retained
on either oligonucleotide (Fig. 4A). This is to be expected, as
whereas it binds mRNAs via its partners eIF4E and PABP, it
should not bind these oligonucleotides as they are neither
capped nor polyadenylated.
PSF and p54nrb were retained on oligonucleotides corre-
sponding to the ARE-containing regions of the TNF, granu-
locyte-macrophage colony stimulating factor, c-Fos, interferon
, and cyclooxygenase 2mRNAs (Fig. 4B). Binding to the TNF
and interferon -based oligoribonucleotides was greatest. A
well knownARE-binding protein, TIA-1, also bound to all these
RNAs (Fig. 4B). Neither TIA-1 nor PSF or p54nrb bound to the
negative control RNA. To study this further, we tested whether
recombinant (bacterially expressed) PSF or p54nrb, alone or in
combination, could bind to the biotinylated TNF ARE-based
oligonucleotide in vitro. When tested alone, little retention of4 S. Rousseau, personal communication.
FIGURE 5. Identification ofMnk phosphorylation sites in PSF. A, PSF or eIF4E (as indicated) were incubated
with Mnk1 or Mnk2 and [-32P]ATP in vitro. Reaction products were detected by autoradiography after SDS-
PAGE. The positions of Mnk1/2, PSF, and eIF4E are indicated. B, Mnk2-phosphorylated PSF was purified by gel
electrophoresis and the excised band containing PSF was treated with trypsin. Phosphorylation sites in the
major tryptic phosphopeptides (a–e) separated by reverse phase chromatography were identified byMALDI-
TOF and solid-phase sequencing. The identities of the sites in each peptide are indicated, as are the retention
time, the 32P radioactivity (solid line), and the acetonitrile concentration (broken line). C, two-dimensional map
of tryptic phosphopeptides derived fromMnk2-phosphorylated PSF.D, two-dimensional maps of tryptic pep-
tides from the PSF S8A and S283A mutants phosphorylated by Mnk2. E, two-dimensional maps of tryptic
phosphopeptides from PSF phosphorylated byMnk1 (upper panel) or Mnk2 (lower panel). The peptide termed
“Linker” corresponds to a serine-rich sequence present beside the His-tag N-terminal to PSF that were phos-
phorylated in vitro by the Mnks. In the proteins used in themaps shown in D, these serines had beenmutated
to alanines to eliminate this. In panels C–E, the direction of chromatography (arrow), polarity of electrophoresis
(/), and the position of the origin are shown. Letters denote peptides discussed in the text. Aminor peptide
seen only in the Mnk1-derived maps is labeled “f.”
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either protein on the RNA was observed (Fig. 4C). Only when
they were added together was substantial binding observed.
The ability to interact with ARE-containing RNA is thus a fea-
ture of the PSFp54nrb complex rather than of either protein
alone, and is a direct interaction, rather than beingmediated via
another mammalian oligopyrimidine tract-binding protein
such as PTB (with which PSF associates (35)).
It was clearly important to establishwhether PSF binds to the
TNFmRNA in vivo. We therefore performed the following IP
RT-PCR experiment, using Jurkat T-cells that had been stimu-
lated with antibodies to CD3 and CD28 rather than HEK293
cells because the latter do not produce TNF. Activated Jurkat
T cells, as well as unstimulated controls, were cross-linked
using formaldehyde. Cell lysates were prepared and PSF was
immunoprecipitated from them. RNA was extracted from the
precipitates and TNF mRNA detected by reverse transcrip-
tion followedbyPCR, using primers in different exons to ensure
that we were looking at mature mRNA. As expected from ear-
lier work (e.g. (18)), stimulation of Jurkat cells greatly increased
the level of TNFmRNA relative to the GAPDH housekeeping
control (assessed by RT-PCR of whole cell lysates, Fig. 4D). In
the PSF IP, a strong signalwas seenwith theTNFPCRprimers
for stimulated cells, whereas no product was observed for non-
treated cells, indicating that PSF binds the TNF mRNA in
vivo. No product was amplified from the anti-PSF pull-down
when GAPDH primers were used (Fig. 4D). This demonstrates
for the first time that PSFp54nrb bind to a specific ARE-con-
taining mRNA in living cells.
Because PSF also interacted in vitro with oligonucleotides
based on the AREs from other mRNAs (Fig. 4B), we also
attempted to perform similar IP RT-PCR studies for additional
mRNAs. As shown in Fig. 4E, PSF was found to bind to the
granulocyte-macrophage colony stimulating factor mRNA in
lysates from stimulated Jurkat cells. However, in experiments
not shown here, no signal was obtained using PCR primers for
the interferon  and interleukin-10 mRNAs. Further analysis
revealed that the levels of these mRNAs are very low in Jurkat
cells stimulated under the conditions used here. Furtherwork is
thus required to establish whichmRNAs do bind specifically to
PSF.
PSF Is Phosphorylated at Two Sites by the Mnks—It was
important to confirm that PSF is indeed an Mnk substrate, as
suggested by the data in Fig. 1A. To do this, we expressed PSF in
E. coli as a hexahistidine-tagged fusion and incubated it with
activatedMnk1 or Mnk2 (Fig. 5A). TheMnks clearly phospho-
rylate recombinant PSF in vitro (here, eIF4E serves as the pos-
itive control). To identify the phosphorylation sites, radiola-
beled PSF was subjected to tryptic digestion and the resulting
peptides were analyzed by reverse-phase HPLC (Fig. 5B) and
two-dimensional mapping (Fig. 5C). Subsequent analysis by
mass spectrometry and Edman degradation revealed that peak
“b” from the reverse-phase HPLC corresponded to a peptide in
which Ser8 was phosphorylated, peak “d” to a species contain-
ing Ser(P)283, and peak “e” to phosphorylated serines in the
thrombin cleavage site of the recombinant fusion protein.
As confirmation of the identification of the sites, the S8A and
S283Amutants of PSFwere prepared and incubatedwithMnk2
in vitro. The radiolabeled proteins were then subjected to tryp-
tic digestion and peptide mapping (Fig. 5D). In the maps from
the S8Amutant, peptide b and the weaker spots termed “a” and
“c” were all absent. They all likely contain Ser8, being generated
by alternative tryptic cleavage as this region contains multiple
arginyl residues. Peptide d was absent in the map from the
S283A mutant. Mnk-mediated phosphorylation of PSF thus
occurs at Ser8 and Ser283. In fact, whereas Ser283 is phosphoryl-
ated similarly by Mnk1 and Mnk2, Mnk2 phosphorylates Ser8
much better thanMnk1 does (Fig. 5E). This is not a reflection of
differences in the relative activities of the two enzymes used in
this assay, because the labeling of peptide d is at least as strong
in the Mnk1-derived map, whereas peptides a–c are much
weaker. Thus the relative levels of the labeling of the different
sites achieved with Mnk1 andMnk2 differ, and these data thus
indicate a difference in specificity between Mnk1 and Mnk2.
One peptide (“f” in Fig. 5E, upper section) is only seen in maps
from PSF phosphorylated by Mnk1: as it is clearly a minor spe-
cies, we have not attempted to identify it.
We then used synthetic phosphopeptides to prepare antisera
for PSF phosphorylated at Ser8 or Ser283. Although we were
unable to generate a functional phospho-Ser283 antibody, the
Ser8 phospho-specific antibodyworkedwell andwas fully phos-
pho-specific, provided that the dephosphopeptide was
included in the incubationswith the primary antibody (i.e. it did
not cross-react with the non-phosphorylated peptide; Fig. 6A).
It was therefore suitable for use to study the phosphorylation of
Ser8 in PSF in HEK293 cells. The antibody detected a band in
the position of PSF (as confirmedusing anti-PSF antiserum, Fig.
6B). The signal detected in serum-starved cells was not
increased by treatment with the phorbol ester TPA (which acti-
vates ERK signaling (36)). This is consistent with this site being
phosphorylated by Mnk2, which has high basal activity that is
not increased much by TPA treatment (16). Also consistent
with this, the signal was essentially eliminated by treating the
FIGURE 6. Characterization and use of a phosphospecific antibody for
Ser8 in PSF. A, dot blot with increasing concentrations of the non-phospho-
rylated (“Ser8”) peptide (SRDRFRSRGGGGC (the final cysteine is not part of the
sequenceof PSF, but is included to facilitate the couplingof thepeptide)) and
the phospho-Ser8 peptide (SRDRFRS(phos)RGGGGC) was developed with
anti-phospho-Ser8 antibody (1g/ml) in the presence or absence of the Ser8
peptide (10 g/ml), as indicated. B, Western blot for endogenous PSF and
phospho-Ser8 in PSF in lysates fromserum-starvedor TPA-stimulatedHEK293
cells. The signal for total PSF serves as the “loading control” for interpreting
the data for the phosphospecific antibody. C, lysates from Jurkat cells were
subjected to immunoprecipitation with anti-PSF or anti-(P)Ser PSF antisera,
or with an isotype-matched negative control antibody (“Con”). Samples were
analyzed by SDS-PAGE/immunoblot with the converse antibodies, as indi-
cated. A sample of lysate was run in parallel as a positive control: the position
of the 100 kDa marker is shown.
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cells with the Mnk1/2-specific inhibitor CGP57380 (37) (Fig.
6B). As a further test of the specificity of the anti-Ser(P)8 anti-
body, we performed immunoprecipitations either with this
antibody or with anti-PSF, and analyzed the immunoprecipi-
tates byWestern blot using the other antibody. As shown in Fig.
6C, in each case a single bandwas observed thatmigrated at the
expected position for PSF, and which was not observed in con-
trol immunoprecipitations (using an isotype-matched negative
control antibody). This confirms that the phosphospecific anti-
body is indeed specific for PSF.
We used the Mnk inhibitor CGP57380 to study whether
phosphorylation of PSF affected its interactions. Treatment of
Jurkat cells with CD3/CD28 and/or CGP57380 did not alter
the binding of PSF to p54nrb (Fig. 7A) or its intracellular local-
ization (always mainly nuclear, as for p54nrb; Fig. 7B). To test
the effect of CGP57380 on the binding of PSF to the TNF
mRNA, we used Jurkat cells, which can be stimulated using
antibodies to CD3 and CD28. Using
the protocol already described in
Fig. 4D, we studied the effect of
CGP57380 on the binding of TNF
mRNA to PSF. Treatment of stimu-
lated Jurkat cells with CGP57380
decreased the binding of PSF to the
TNFmRNA, as shownby standard
PCR (Fig. 7C) and, quantitatively, by
Q-PCR (Fig. 7D, left-hand panel).
As reported earlier, CGP57380 did
not affect total TNF mRNA levels
as assessed by standard (Fig. 7C) or
Q-PCR (Fig. 7D, right-hand panel).
This suggests that Mnk-mediated
phosphorylation enhances the
binding of PSF to the TNFmRNA.
As PSF occurs both in the nucleus
and cytoplasm, PSF phosphoryla-
tionmight play a role in transport of
the TNFmRNA to the cytoplasm.
However, treatment of Jurkat cells
with CGP57380 did not affect the
relative amounts of TNFmRNA in
these compartments (Fig. 7E).
DISCUSSION
This study identifies PSF as a
novel substrate for the Mnks and as
binding to mRNAs, such as that for
TNF, that possess AREs. We show
that PSFp54nrb is retained on bio-
tinylated RNAs that contain AREs,
demonstrating a specific function
for PSFp54nrb complexes. Indeed,
PSF and p54nrb bind to several oli-
goribonucleotides that are based on
ARE-containing mRNAs including
ones encoding cytokines, imme-
diate early genes, or other pro-
teins involved in inflammation.
PSFp54nrb may be important in regulating such mRNAs.
Importantly, we show that PSF associates specifically with the
TNF mRNA, but not to a “negative control,” the GAPDH
mRNA, in living cells. It is likely that this specificity is conferred
by the ARE in the 3-untranslated region of the TNFmRNA.
Our initial identification of PSFp54nrb as proteins present in
material retained on cap resin is likely explained by the reten-
tion of mRNAs on this resin, by virtue of their interaction with
proteins that bind to eIF4E. This interpretation is supported by
the observation that treatment of the resin-boundmaterial with
RNase greatly decreased the recovery of PSF and p54nrb. It is
also consistent with the fact that another protein that binds the
3-untranslated region of mRNAs (PABP) is also retained on
m7GTP-Sepharose.
Here, we identify two sites in PSF, Ser8 and Ser283, which can
be phosphorylated by the Mnks in vitro. We show, using a new
phosphospecific antiserum, that Ser8 is phosphorylated within
FIGURE 7.Mnk inhibition does not affect the interaction between PSF and p54nrb or the nucleocytoplas-
mic localization of these proteins or of the TNFmRNA. A, Jurkat cells were either left untreated or stimu-
lated with anti-CD3/anti-CD28. Where indicated, cells were treated with 40 M CGP57380 for 45 min before
stimulation. After 1 h of stimulation, cells were harvested and anti-PSF-coated protein G beads were used to
immunoprecipitate PSF from the cell extracts. The presence of PSF and p54nrb in the pull-downs was analyzed
byWestern blotting. B, extracts from Jurkat cells treated as in A, were fractionated to give cytoplasmic (C) and
nuclear (N) fractions. Aliquots of each fraction were analyzed by Western blotting with antibodies directed
against PSF and p54nrb, and also with anti-lamin B and -tubulin as controls for the efficiency of the fraction-
ation. C, TNF andGAPDHmRNA levels from total cell lysates or PSF IPs, from Jurkat cells, thatwere untreated or
stimulated in the presence or absence of CGP57380 (40M).D, as C, butmRNA levels were also analyzed by RT
Q-PCR. E, Jurkat cells were treated as indicated. Lysates were then prepared and fractionated. Total RNA was
extracted from 100 g of nuclear (N) or cytoplasmic (C) fractions using the TRIzol method. RNA levels were
analyzed by RT Q-PCR.
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cells, and that its phosphorylation is blocked by theMnk inhib-
itor CGP57380, thus identifying PSF as a new intracellularMnk
substrate. Interestingly, Ser8 was preferentially phosphorylated
by Mnk2, providing the first evidence for differences between
the specificities of Mnk1 andMnk2. FewMnk substrates are so
far known, and most are involved in mRNA translation or
metabolism (eIF4E (10, 13), eIF4G (28), and heterogeneous
nuclear ribonucleoprotein A1 (18)), although a fifth one,
Sprouty, modulates cyoplasmic signaling (37). Binding of PSF
to the TNFmRNA in Jurkat T cells was decreased by treating
cells with the Mnk inhibitor CGP57380. Phosphorylation of
PSF appears to favor binding to the TNF mRNA. PSF is
thoughtmainly to participate in nuclear events (1). TheMnk2b
isoform is nuclear (14). It is therefore attractive to speculate
that its Mnk-regulated ability to bind the TNF mRNA (and
likely otherARE-containingmRNAs) plays a role inmodulating
the nuclear processing of such mRNAs or their transport into
the cytoplasm.
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